Vaccine registration in the EAEU and Russia. Dossier specifics and release of each batch


A registration certificate alone is not enough to sell a manufactured vaccine batch. Vaccines are immunobiological medicinal products (IBPs), and each batch of such a product is released into civil circulation under a permit from Roszdravnadzor. The permit is issued on the basis of a conclusion from a federal budgetary institution (FSBI) that has tested samples of that particular batch (under Federal Law No. 61-FZ of 12 April 2010 «On the Circulation of Medicines», hereinafter 61-FZ).
Vaccine registration in the Eurasian Economic Union (EAEU) follows the Rules for Registration and Regulatory Assessment of Medicines for Medical Use approved by Decision No. 78 of the Council of the Eurasian Economic Commission (EEC) of 3 November 2016 (hereinafter Rules No. 78). For vaccines, they set separate requirements for Module 3 of the registration dossier (the data on product quality). Non-clinical and clinical data are prepared under the vaccine chapters of the Rules for Conducting Studies of Biological Medicines of the EAEU approved by Decision No. 89 of the EEC Council of 3 November 2016 (hereinafter Rules No. 89).

Which products count as immunobiological

Immunobiological products are those intended to produce active or passive immunity, or to diagnose the presence of immunity or a specific acquired change in the immune response to allergenic substances: vaccines, toxoids, toxins, sera, immunoglobulins and allergens (under 61-FZ). A separate procedure for releasing batches into circulation applies to all of these products, and vaccines are among them.
Under 61-FZ, a manufacturer or importer submits a manufacturer’s document on quality and a confirmation from a qualified person (QP) for all products except immunobiological ones. IBPs follow a separate procedure, described below.

Vaccine antigen master file in Module 3 of the dossier

Module 3 of a vaccine dossier is prepared under Rules No. 78, with a separate section for vaccines. Instead of the general requirements for the section «Active pharmaceutical substance», vaccines use the vaccine antigen master file (VAMF), a separate part of the dossier with biological, pharmaceutical and chemical information on each active substance.
If a vaccine is not intended for the prevention of human influenza, the dossier includes a VAMF for each vaccine antigen contained in it as an active substance. The number of active substances equals the number of antigens. A monovalent vaccine contains one antigen for the prevention of one infectious disease; a combined (polyvalent) vaccine contains at least two different antigens. One VAMF may be shared by several monovalent and combined vaccines filed by the same applicant or registration holder.

The VAMF contains the following information from the «Active pharmaceutical substance» section of Module 3:
General information, including compliance with the monograph of the EAEU Pharmacopoeia or, if there is none, with the monographs of the pharmacopoeias of member states or of the principal pharmacopoeias.
Information on the manufacturer of the active substance: manufacturing process, starting materials and raw materials, specific measures against spongiform encephalopathies, assessment of safety with respect to adventitious infectious agents, premises and equipment.
Characterization of the active substance.
Quality control of the active substance.
Reference standards and materials.
Primary packaging and closure system of the active substance.
Stability of the active substance.

For a new antigen, the applicant files a full dossier with a VAMF for that antigen if no such VAMF exists yet. If the assessment is positive, an EAEU conclusion on the VAMF (a certificate) is issued together with an assessment report, and it is valid across the whole EAEU. The same rules apply to a new combination of antigens, even if some of them are already part of vaccines registered in member states. Changes to a VAMF are assessed under the variation procedure, and the conclusion issued is accepted by the authorized bodies of the member states at registration, confirmation of registration and variation.
The registration application forms state whether a certificate for the VAMF used in the dossier has been issued or an application for it has been filed. They also name the laboratory of the manufacturer’s country that controls the quality and release of batches of blood products and vaccines.

As for other biological products, additional requirements for the section on manufacture of the substance apply to vaccines:
manufacture must be based, where possible, on a seed lot system and known cell banks;
for bacterial and viral vaccines, the characteristics of the pathogen are confirmed on the seed material;
for live vaccines, the stability of attenuation (reduced virulence) is confirmed on the seed material and, if that is not enough, at the production stage;
seed materials, cell banks and other materials of biological origin are screened for adventitious agents; if potentially pathogenic agents cannot be avoided, the material is used only when subsequent processing removes or inactivates them and this has been validated.

In the stability section for the finished product, cumulative stability information is provided for vaccines where necessary.

Simplified dossier for vaccines produced before 2000

Rules No. 78 allow a simplified dossier if the vaccine antigen is well studied in medical use, efficacy and an acceptable level of safety are confirmed, and production in the territories of member states was carried out before 2000. In that case Module 3 is prepared under the general requirements of Rules No. 78 for Module 3 and the rules on the VAMF. Instead of reports on non-clinical and clinical studies in Modules 4 and 5, a scientific bibliographic review is submitted that describes the non-clinical and clinical characteristics of the vaccine.

Where to find non-clinical and clinical data requirements

Table 1. Topics of Rules No. 89 for vaccines

SubjectWhat Rules No. 89 cover
Adjuvants and the «adjuvant and antigen» complexQuality of the adjuvant, the complex and the final product, non-clinical studies, clinical studies
Thiomersal (preservative) in vaccinesRemoval, reduction of concentration or replacement of thiomersal
Influenza vaccines, qualityQuality requirements for seasonal, pre-pandemic and pandemic vaccines and for live attenuated vaccines
Influenza vaccines, non-clinical and clinical studiesImmunogenicity, protectiveness, clinical studies
Smallpox vaccinesGuidance on developing smallpox vaccines

Under Rules No. 89, thiomersal-free vaccines should be used to vaccinate infants and young children. The efficiency of physicochemical removal of the preservative is confirmed on at least three vaccine batches. The residual preservative concentration is set and included in the specification; if the assay method is not sensitive enough, the value may be set by calculation.
For non-clinical assessment of influenza vaccines, Rules No. 89 require assessing immunogenicity (the ability to induce an immune response) in small laboratory animals, including the humoral and cellular response and the dose-effect relationship. Protectiveness (the ability to protect against infection) is assessed in a suitable animal model for vaccines with new mechanisms of action and where there are no clinical data on use in humans, for example when pandemic vaccines are being developed. For new vaccines to which these requirements apply only in part, the applicant may ask the authorized bodies of the member states for scientific advice.
Under Rules No. 89, smallpox vaccines fall into three groups: first-generation vaccines produced using live animals, second-generation vaccines grown on tissue cultures or chicken embryos, and third-generation vaccines containing viruses obtained by genetic engineering or gene transfer technologies.

Influenza vaccines at the annual strain change and in a pandemic

The VAMF requirement does not apply to influenza vaccines. For them, Rules No. 78 provide a separate procedure: changes to the strain composition and the registration of seasonal, pandemic and pre-pandemic vaccines follow it.
An application for a change to the strain composition of a seasonal vaccine is filed after the authorized body officially announces that it is accepting such applications, which follows the annual recommendations of the World Health Organization (WHO), and before the deadline set by the authority of the reference state (the member state that prepares the assessment report on the safety, efficacy and quality of the product). In the «Name of the change» field of the application form, the applicant enters «Annual update of the strain(s) of a vaccine for the prevention of influenza». Under this procedure the applicant may not make other changes, and the authorities may not require them, except changes caused by the new strain. Other changes are made under the general variation procedure of Rules No. 78.
The authorized body of the reference state assesses the completeness and correct execution of the documents within 5 working days of filing, and the assessment takes no more than 19 working days from the notification of the applicant that the procedure has started. The applicant answers a request from the assessing organization within 7 working days, and this period is not counted in the overall time limit of the procedure.
If the WHO or the member states have recognized a pandemic influenza situation, the authorized bodies may temporarily accept a change to the registration terms of the vaccine when certain non-clinical or clinical data are missing. After approval, the applicant submits the missing data by the deadline set by the authority of the member state.

How a vaccine batch gets a permit for release into circulation

The procedure for issuing the permit and the conclusion was approved by Resolution of the Government of the Russian Federation No. 815 of 31 May 2025 «On the Procedure for Releasing Medicines for Medical Use into Civil Circulation» (hereinafter Resolution No. 815). The Resolution has been in force since 10 June 2025 for 6 years, that is, until 10 June 2031. It approved the Rules for Issuing a Permit for the Release into Civil Circulation of a Batch or Lot of an Immunobiological Medicinal Product and a Conclusion on Its Compliance (hereinafter the Permit Issuance Rules). Before it, the rules on this subject were contained in Resolution of the Government of the Russian Federation No. 1510 of 26 November 2019 «On the Procedure for Releasing Medicinal Products for Medical Use into Civil Circulation» (hereinafter Resolution No. 1510; as stated in the Commentary by A.N. Borisov on 61-FZ, 2026). The rules approved by Resolution No. 1510 were repealed by Resolution of the Government of the Russian Federation No. 816 of 31 May 2025 «On Amendments to Certain Acts of the Government of the Russian Federation» (hereinafter Resolution No. 816). The amendments took effect seven days after official publication on 2 June 2025, and the edition of Resolution No. 1510 as amended has applied since 10 June 2025. Resolution No. 1510 itself remains in force in its other parts, and the rules on issuing the permit are no longer in it.
To release an IBP batch produced in Russia or imported into Russia, a conclusion from one of the accredited federal budgetary institutions (FSBIs) subordinate to the Ministry of Health and/or Roszdravnadzor is needed first: the institution tests samples of the batch and confirms that it complies with the requirements established at registration. Roszdravnadzor then issues the permit on the basis of the conclusion.

Table 2. Issuance of the conclusion and the permit under the Permit Issuance Rules

StageWho actsTime limit
Application for a conclusion with documents is filed with one of the FSBIsManufacturer or importer (applicant)No time limit specified
Registration of the application and check of completenessFSBI3 working days from receipt
Reply to the FSBI’s request for missing materialsApplicantNo more than 30 working days from receipt of the request
Calculation of the number of samples, request for samples, notice of the fee and payment detailsFSBI3 working days from receipt of the application
Submission of samples and details of the payment documentApplicantNo more than 90 working days from receipt of the application for a conclusion; if samples for reproducing the methods have to be purchased or imported, an extension of no more than 30 working days on application
Quality testsFSBINo more than 30 working days from receipt of the samples and payment details; longer if the methods require it
Execution of the conclusion with the test protocolFSBI3 working days after the tests are completed
Application for a permit through the personal account in the Roszdravnadzor information system or through the Gosuslugi portalApplicantNo time limit specified
Issuance of the permit (entry in the permit register)Roszdravnadzor3 working days from receipt of the application

The application for a conclusion is accompanied by:
a copy of the manufacturer’s document on the production stages and quality control of the batch in line with the documents of the registration dossier;
a copy of the manufacturer’s document confirming that the quality of the batch meets the requirements established at registration;
a confirmation from the applicant’s qualified person (QP) that the batch meets those requirements;
a copy of the normative documentation or normative document on quality;
for products registered under EAEU law, mock-ups of the primary, intermediate (if any), secondary (consumer) and group (if any) packaging;
the consent of the registration holder (owner) to verification of the accuracy of the data and its consistency with the registration dossier documents, including by an FSBI request to the federal institution that carries out the expert review of medicines (named in 61-FZ)
.

Samples are requested in a quantity that allows the quality control methods to be reproduced twice. The scope of tests is determined by the Roszdravnadzor commission on the quality of IBPs.
A fee of 2,000 rubles is charged for issuing the conclusion. The FSBI calculates the cost of the tests themselves using the Ministry of Health methodology and notifies the applicant of it together with the request for samples.
The conclusion will be refused if the applicant does not submit, on time, a reply to the FSBI’s request, the required number of samples or the details of the payment document. If the tests reveal deviations from the registration requirements, the FSBI issues a conclusion of non-compliance and sends it to Roszdravnadzor.
Roszdravnadzor will refuse the permit within 3 working days if the application contains incomplete or inaccurate information, if the medicines movement monitoring system has no data on the batch, or if a repeat application has been filed for which a permit has already been issued. The refusal can be appealed. The permit register states, among other things, the batch number, the trade name, the registration certificate number, the manufacturer that carries out release quality control, and the manufacturers performing the production stages.
The forms of the FSBI conclusion, the extract from the permit register and the notice of refusal were approved by Roszdravnadzor Order No. 5242 of 25 September 2025. In the conclusion, the FSBI lists the documents reviewed from the list above, gives the batch data and states a finding of «complies» or «does not comply» with the requirements established at registration; the test protocol is attached.
A batch may not be released into circulation without a permit. If Roszdravnadzor finds an IBP batch in circulation without a permit, it decides to end the civil circulation of that batch until a permit is obtained.
For other products, 61-FZ provides for a test protocol for the first three batches, its replacement for the first batch where GMP documents are available (documents on the compliance of production with good manufacturing practice requirements), and an annual protocol. The exclusion of IBPs from the general procedure of the manufacturer’s document and the QP confirmation is expressly written in the law. The provisions on the three-batch protocol, its replacement and the annual protocol do not name IBPs: their text contains neither an exclusion nor a direct reference to IBPs. In the provisions on exceptions and on termination of circulation, the law lists documents under other rules next to the permit for IBPs. In the provision on exceptions these are the documents of the general procedure and the protocol of the first three batches; in the provision on termination of circulation they also include the replacement protocol, the annual protocol and other documents.
A.N. Borisov’s Commentary (2026) sets out these provisions separately and does not explain whether the three-batch protocol, its replacement and the annual protocol apply to IBPs in addition to the permit. The title of the rules for issuing the test protocol for the first three batches under Resolution No. 1510 contained the words «except for an immunobiological medicinal product» (Roszdravnadzor Letter of 28 November 2019); the title of the equivalent rules in Resolution No. 815 has no such exception. The 2019 letter relates to rules that have lost force, so it is cited as a reference to the agency’s earlier position and not as a current clarification. On the annual protocol, the 2019 letter does not mention IBPs.
The law exempts from the documents of the general procedure, from the protocol of the first three batches and from the permit products intended for clinical studies and for expert review at state registration, as well as unregistered products imported for the vital needs of a particular patient or group of patients under the procedure set by 61-FZ.

Who determines the scope of tests for a batch

The scope of tests for each product name and manufacturer (taking into account the dosage form and strength) is determined by the Roszdravnadzor commission on the quality of IBPs. The commission was established by Roszdravnadzor Order No. 5228 of 22 September 2025, which also approved the regulations on it. The procedure for assessing the scope was approved by Order No. 5227 of 22 September 2025. Both orders remain in force until 10 June 2031.
The membership of the commission is approved by the head of Roszdravnadzor, and it has at least 10 members. Meetings are held in person or by videoconference, decisions are taken by open vote by simple majority and are valid if at least half of the members are present. The commission may involve independent experts and hear representatives of the manufacturer or importer.

Order No. 5227 sets the following assessment procedure:
1. Registered IBPs that have been released into circulation and entered in the Roszdravnadzor information system are assessed. Each year, by 1 March, the FSBIs submit to the commission an analysis of the quality of these products.
2. By 1 April each year the commission holds a meeting and determines the scope and frequency of tests by the indicators of the normative documentation. The decision is posted on the Roszdravnadzor website within 5 working days. Extraordinary meetings are possible when the normative documentation changes, new products are registered, quality deteriorates, or there are problems with efficacy or safety.
3. The scope of tests is reduced (except for significant quality indicators) only if none of the following circumstances is present: information on non-compliance with registration requirements; information on serious adverse reactions, threat to life, harm to health or clusters of cases of insufficient efficacy; statistical analysis results going beyond the limits of reliability; gross violations of licensing requirements and critical deficiencies found in a GMP inspection.
4. For an IBP produced or imported for the first time, the decision to reduce the scope is made after at least 15 batches have been tested by each FSBI.
5. The manufacturer or importer may file with Roszdravnadzor an application to change the commission’s decision; the commission considers it for no more than two calendar months from registration.
6. When information arrives on non-compliance of quality, serious adverse reactions, gross violations of licensing requirements or critical deficiencies under GMP, the commission increases the scope of tests. Roszdravnadzor also passes to the commission information on the deterioration of the quality of the product or of the conditions of its production; the commission may change its earlier decision.

Remote testing of a batch

Quality tests of an IBP can be carried out using remote interaction tools. The grounds and procedure are set out in separate Rules for Conducting Tests, Including with the Use of Remote Interaction Tools, approved by Resolution No. 815 (hereinafter the Testing Rules).
They name the cases in which remote tests are carried out:
The FSBI does not have the special testing or auxiliary equipment that the normative documentation requires.
Samples of the product or samples for reproducing the methods cannot be transported to Russia or stored there.
Features of production or quality control do not allow the tests to be carried out in Russia without damaging the whole batch.
The specification includes indicators that can be tested only at the manufacturer’s site or in a laboratory authorized by the manufacturer and named in the dossier.

Tests are carried out by visiting the manufacturer’s site or its laboratory and/or online in real time, including video materials for individual indicators. If the equipment is missing, the FSBI itself decides on remote tests within 5 working days of receiving the request. In the other three cases the applicant files an application for remote tests together with the request, with a justification and supporting materials. The FSBI checks the information and takes a decision within 5 working days of registration of the application; it will refuse if the information is incomplete or inaccurate or the justification is missing.

Remote tests take no more than 30 working days from notification of the decision, and if the method requires more time, the period is extended by that time. For online tests the period can be extended on application by no more than 30 further working days. After the tests, within 3 working days the FSBI may request supporting documents: environmental condition readings, quality of reagents and materials, quality and housing conditions of laboratory animals, equipment qualification documents, primary data and technical records. The applicant replies in no more than 30 working days (the Permit Issuance Rules provide the same for IBPs).
The Testing Rules are written for a request for issuance of a test protocol, whereas for IBPs an application for a conclusion is filed. The Resolution does not state directly how to file an application for remote tests together with an application for a conclusion; as of the date of verification, this question is not regulated in the act.

What to do

Identify the type of vaccine and the applicable requirements. For an influenza vaccine, see the separate procedure of Rules No. 78 and the vaccine chapters of Rules No. 89 on quality and on non-clinical and clinical studies; for other vaccines, the VAMF requirements of Rules No. 78 and the vaccine chapters of Rules No. 89 from Table 1: adjuvants, thiomersal, smallpox vaccines. For a vaccine produced before 2000, check the conditions for a simplified dossier.
Check the master files. A vaccine other than an influenza vaccine needs a VAMF for each antigen; if it contains a new antigen or a new combination of antigens, the VAMF is assessed together with the dossier and receives an EAEU conclusion. In the application form, state whether a certificate for the VAMF has been issued or an application for it has been filed.
Prepare the batch package in advance. A vaccine batch is released under the procedure for IBPs: an FSBI conclusion and a Roszdravnadzor permit. Whether the three-batch protocol, its replacement and the annual protocol apply to IBPs is unclear from the text of the law, so before the first batch is released, ask Roszdravnadzor for its position in writing. The list of documents for the application is given above; separately, decide who signs the QP confirmation and how the registration holder will give consent to verification of the data against the dossier.
Build the time limits for the conclusion and the permit into the schedule. The maximum time limits for the stages run in sequence: 90 working days to submit samples and the payment document, up to 30 working days for tests, 3 working days to execute the conclusion and 3 working days to issue the permit; methods with longer procedures extend the tests. Find the commission’s decision for your product name on the Roszdravnadzor website: it determines the scope and frequency of tests. The FSBI requests samples for reproducing the methods (test strains, cell cultures, reference substances, consumables) in a quantity sufficient to reproduce the methods twice; if they have to be purchased or imported, file an application for an extension.
Check the batch data in the monitoring system. Before filing the application for a permit, make sure the batch data have been entered in the medicines movement monitoring system: if they are missing, Roszdravnadzor will refuse the permit. The application is filed as an electronic document signed with an enhanced electronic signature.
Prepare a justification for remote tests. If the tests require equipment, samples or a site that are not available in Russia, prepare a justification for one of the cases listed above. Before filing, agree with the chosen FSBI in what form and with what document to file the application for remote tests: the procedure for an application for a conclusion is not directly established in the Resolution.

For an influenza vaccine, prepare the strain change in advance: the application is filed during the acceptance period that the authorized body opens after the WHO recommendations, and no other changes are included in this procedure.


Regulatory framework:

1. Decision of the Council of the Eurasian Economic Commission No. 78 of 3 November 2016 «On Approval of the Rules for Registration and Regulatory Assessment of Medicines for Medical Use» (as amended 26 November 2025)
2. Decision of the Council of the Eurasian Economic Commission No. 89 of 3 November 2016 «On Approval of the Rules for Conducting Studies of Biological Medicines of the Eurasian Economic Union» (as amended 22 January 2025)
3. Roszdravnadzor Order No. 5227 of 22 September 2025 «On Approval of the Procedure for Assessing the Scope of Quality Tests of Immunobiological Medicinal Products by the Commission of the Federal Service for Surveillance in Healthcare on the Quality of Immunobiological Medicinal Products» (registered by the Ministry of Justice of Russia on 22 October 2025, No. 83910)
4. Roszdravnadzor Order No. 5228 of 22 September 2025 «On the Commission of the Federal Service for Surveillance in Healthcare on the Quality of Immunobiological Medicinal Products» (registered by the Ministry of Justice of Russia on 22 October 2025, No. 83909)
5. Roszdravnadzor Order No. 5242 of 25 September 2025 «On Approval of the Form of the Conclusion on Compliance of a Batch or Lot of an Immunobiological Medicinal Product with the Requirements Established at Its State Registration or Registration, the Form of the Extract from the Register of Permits … and the Form of the Notice to the Applicant of the Decision to Refuse a Permit …» (registered by the Ministry of Justice of Russia on 24 October 2025, No. 83946)
6. Federal Law No. 61-FZ of 12 April 2010 «On the Circulation of Medicines» (as amended 4 August 2026)
7. Resolution of the Government of the Russian Federation No. 815 of 31 May 2025 «On the Procedure for Releasing Medicines for Medical Use into Civil Circulation» (in force from 10 June 2025 to 10 June 2031), including the Rules for Issuing a Permit for the Release into Civil Circulation of a Batch or Lot of an Immunobiological Medicinal Product and a Conclusion on Its Compliance and the Rules for Conducting the Tests Specified in Parts 4, 4.1, 4.3 and 5 of Article 52.1 of the Federal Law «On the Circulation of Medicines», Including with the Use of Remote Interaction Tools
8. Resolution of the Government of the Russian Federation No. 816 of 31 May 2025 «On Amendments to Certain Acts of the Government of the Russian Federation»
9. Resolution of the Government of the Russian Federation No. 1510 of 26 November 2019 «On the Procedure for Releasing Medicinal Products for Medical Use into Civil Circulation» (as amended 31 May 2025)
10. Roszdravnadzor Letter No. 01I-2906/19 of 28 November 2019 «On Release into Civil Circulation» (on the procedure under the rules of Resolution No. 1510, which ceased to be in force on 10 June 2025)
11. Borisov, A.N. Commentary on Federal Law No. 61-FZ of 12 April 2010 «On the Circulation of Medicines» (article-by-article). 2nd ed., revised and expanded. Moscow: Yustitsinform, 2026.

This page in Russian→